179 related articles for article (PubMed ID: 29440001)
1. Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.
Beukelman T; Xie F; Chen L; Horton DB; Lewis JD; Mamtani R; Mannion MM; Saag KG; Curtis JR
Ann Rheum Dis; 2018 Jul; 77(7):1012-1016. PubMed ID: 29440001
[TBL] [Abstract][Full Text] [Related]
2. Psoriasis Associated With Tumor Necrosis Factor Inhibitors in Children With Inflammatory Diseases.
Buckley LH; Xiao R; Perman MJ; Grossman AB; Weiss PF
Arthritis Care Res (Hoboken); 2021 Feb; 73(2):215-220. PubMed ID: 31646743
[TBL] [Abstract][Full Text] [Related]
3. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Buchbinder R; Van Doornum S; Staples M; Lassere M; March L
BMC Musculoskelet Disord; 2015 Oct; 16():309. PubMed ID: 26481039
[TBL] [Abstract][Full Text] [Related]
4. Rates of malignancy associated with juvenile idiopathic arthritis and its treatment.
Beukelman T; Haynes K; Curtis JR; Xie F; Chen L; Bemrich-Stolz CJ; Delzell E; Saag KG; Solomon DH; Lewis JD;
Arthritis Rheum; 2012 Apr; 64(4):1263-71. PubMed ID: 22328538
[TBL] [Abstract][Full Text] [Related]
5. Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.
Lee WJ; Briars L; Lee TA; Calip GS; Suda KJ; Schumock GT
Pharmacotherapy; 2016 Dec; 36(12):1201-1209. PubMed ID: 27779782
[TBL] [Abstract][Full Text] [Related]
6. Risk of malignancy in children with juvenile idiopathic arthritis not treated with biologic agents.
Nordstrom BL; Mines D; Gu Y; Mercaldi C; Aquino P; Harrison MJ
Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1357-64. PubMed ID: 22511558
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor-α inhibitor-induced psoriasis in juvenile idiopathic arthritis patients.
Groth D; Perez M; Treat JR; Castelo-Soccio L; Nativ S; Weiss PF; Lapidus S; Perman MJ
Pediatr Dermatol; 2019 Sep; 36(5):613-617. PubMed ID: 31240749
[TBL] [Abstract][Full Text] [Related]
8. Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs.
Baggett K; Brandon TG; Xiao R; Valenzuela Z; Buckley LH; Weiss PF
J Rheumatol; 2022 Aug; 49(8):935-941. PubMed ID: 35428721
[TBL] [Abstract][Full Text] [Related]
9. Psoriasis rate is increased by the exposure to TNF inhibition in children with JIA.
Zhao Y; Sullivan E; Son MB; Beukelman T
Ann Rheum Dis; 2022 May; 81(5):662-665. PubMed ID: 35086815
[TBL] [Abstract][Full Text] [Related]
10. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?
Chen Y; Friedman M; Liu G; Deodhar A; Chu CQ
Cytokine; 2018 Jan; 101():78-88. PubMed ID: 27688201
[TBL] [Abstract][Full Text] [Related]
11. Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis.
Lee WJ; Lee TA; Suda KJ; Calip GS; Briars L; Schumock GT
Rheumatology (Oxford); 2018 Feb; 57(2):273-282. PubMed ID: 28431162
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study.
Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski M; Farley J
J Rheumatol; 2014 Nov; 41(11):2129-36. PubMed ID: 25086079
[TBL] [Abstract][Full Text] [Related]
13. Impact of medication withdrawal method on flare-free survival in patients with juvenile idiopathic arthritis on combination therapy.
Chang CY; Meyer RM; Reiff AO
Arthritis Care Res (Hoboken); 2015 May; 67(5):658-66. PubMed ID: 25220674
[TBL] [Abstract][Full Text] [Related]
14. Population-based cohort study on the risk of malignancy in East Asian children with juvenile idiopathic arthritis.
Kok VC; Horng JT; Huang JL; Yeh KW; Gau JJ; Chang CW; Zhuang LZ
BMC Cancer; 2014 Aug; 14():634. PubMed ID: 25174953
[TBL] [Abstract][Full Text] [Related]
15. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry.
Fiorentino D; Ho V; Lebwohl MG; Leite L; Hopkins L; Galindo C; Goyal K; Langholff W; Fakharzadeh S; Srivastava B; Langley RG
J Am Acad Dermatol; 2017 Nov; 77(5):845-854.e5. PubMed ID: 28893407
[TBL] [Abstract][Full Text] [Related]
16. Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs.
Atzeni F; Carletto A; Foti R; Sebastiani M; Panetta V; Salaffi F; Bonitta G; Iannone F; Gremese E; Govoni M; Marchesoni A; Favalli EG; Gorla R; Ramonda R; Sarzi-Puttini P; Ferraccioli G; Lapadula G;
Joint Bone Spine; 2018 Jul; 85(4):455-459. PubMed ID: 28893679
[TBL] [Abstract][Full Text] [Related]
17. Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study.
Staples MP; March L; Hill C; Lassere M; Buchbinder R
BMC Rheumatol; 2019; 3():1. PubMed ID: 30886989
[TBL] [Abstract][Full Text] [Related]
18. Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.
Hellgren K; Dreyer L; Arkema EV; Glintborg B; Jacobsson LT; Kristensen LE; Feltelius N; Hetland ML; Askling J;
Ann Rheum Dis; 2017 Jan; 76(1):105-111. PubMed ID: 27147709
[TBL] [Abstract][Full Text] [Related]
19. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
20. Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study.
Stoll ML; Grubbs JA; Beukelman T; Mannion ML; Jester TW; Cron RQ; Crain MJ
Pediatr Rheumatol Online J; 2017 Nov; 15(1):79. PubMed ID: 29121953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
